MGRC.KL

Malaysian Genomics Sees Rise in Profit Margins for 1Q

Retrieved on: 
Wednesday, November 23, 2022

The Group recorded a 254.16% increase in profit before tax (PBT) to RM0.85 million for 1Q 2023, compared with RM0.24 million in the corresponding quarter of the previous financial year, on higher profit margins and revenue contributions from the new biopharmaceutical business.

Key Points: 
  • The Group recorded a 254.16% increase in profit before tax (PBT) to RM0.85 million for 1Q 2023, compared with RM0.24 million in the corresponding quarter of the previous financial year, on higher profit margins and revenue contributions from the new biopharmaceutical business.
  • Earnings per share for 1Q 2023 stood at 0.68 sen compared with 0.20 sen in 1Q 2022.
  • Dato' Seri Dr Chen Chaw Min, Independent Non-Executive Chairman of Malaysian Genomics said, "The Group's pivot to immunotherapy and cell therapies from vaccine distribution continues to pay off as PBT improves on higher profit margins.
  • Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/
    Copyright 2022 ACN Newswire .

Malaysian Genomics Signs Strategic Collaboration Agreement for Expansion in the UAE

Retrieved on: 
Wednesday, October 26, 2022

United Arab Emirates (UAE), Oct 26, 2022 - (ACN Newswire) - Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, today announced the signing of a Strategic Collaboration Agreement (SCA) outlining partnerships to market and distribute the Group's Dtect(R) range of genetic screening services in the United Arab Emirates (UAE).

Key Points: 
  • United Arab Emirates (UAE), Oct 26, 2022 - (ACN Newswire) - Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, today announced the signing of a Strategic Collaboration Agreement (SCA) outlining partnerships to market and distribute the Group's Dtect(R) range of genetic screening services in the United Arab Emirates (UAE).
  • IAC will also be the point of contact between Malaysian Genomics and ASC, Balsam and Wellness by Design.
  • Malaysian Genomics' role will be to provide technical and scientific support under the SCA.
  • Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/
    Copyright 2022 ACN Newswire .

Malaysian Genomics Signs Agreement with National Institutes of Health to Explore Research Opportunities

Retrieved on: 
Wednesday, October 12, 2022

The National Institutes of Health (NIH), the research arm under the Ministry of Health Malaysia, comprises six research institutes that focus on biomedical research, public health and epidemiology, clinical research, behavioural health research, health management and health policies.

Key Points: 
  • The National Institutes of Health (NIH), the research arm under the Ministry of Health Malaysia, comprises six research institutes that focus on biomedical research, public health and epidemiology, clinical research, behavioural health research, health management and health policies.
  • The NIH is mandated to conduct high-impact health research to improve the quality of life of the Rakyat.
  • The health research conducted by the NIH is in line with the Health Research Priority Areas for each five-yearly Malaysia Plans.
  • Under this agreement, the parties will explore joint training in the field of medical research, exchange research materials, and partake in scientific data presentation and publication.

Malaysian Genomics Grows Presence in Thailand

Retrieved on: 
Friday, September 23, 2022

Acquest is a well-established provider of various cell therapies to hospitals, specialist doctors, and patients in Thailand.

Key Points: 
  • Acquest is a well-established provider of various cell therapies to hospitals, specialist doctors, and patients in Thailand.
  • Chief Executive Officer of Malaysian Genomics, Encik Sasha Nordin, said, "We are looking forward to a fruitful relationship with our Thai partners, Salus and Acquest.
  • We look forward to collaborating with Malaysian Genomics and with Salus Healthcare on research and development involving cell regeneration products."
  • Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/
    Copyright 2022 ACN Newswire .

Malaysian Genomics, Rinani Genotec Sign LOI with Universiti Malaysia Sabah

Retrieved on: 
Wednesday, September 21, 2022

Parties agree to collaborate on research in genetics, regenerative and alternative medicine

Key Points: 
  • Parties agree to collaborate on research in genetics, regenerative and alternative medicine
    PETALING JAYA, Malaysia, Sept 21, 2022 - (ACN Newswire) - Leading genomics and biopharmaceutical specialist Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155) is pleased to report that the Group has signed a letter of intent (LOI) with the Faculty of Science and Natural Resources, Universiti Malaysia Sabah (UMS) and Rinani Genotec Sdn Bhd (Genotec) to collaborate on research and development (R&D) in genetics, and regenerative and alternative medicines.
  • Chairman of Malaysian Genomics, Datuk Seri Dr. Chen Chaw Min, said, "We are happy to assist UMS undergraduates in pursuing their R&D goals so that they have a better understanding of their field of study.
  • The signing of the LOI followed UMS' visit to MGRC's Biosafety Level 2 cGMP (Current Good Manufacturing Practice)-certified laboratory, which is used for the production of cell therapies, including CAR T-cell therapies for various cancers.
  • Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/
    Copyright 2022 ACN Newswire .

Malaysian Genomics Reports RM28.36 Million Full-Year Revenue

Retrieved on: 
Tuesday, August 30, 2022

For the financial year ended 30 June 2022 (FY2022), Malaysian Genomics registered revenue of RM28.36 million, which is an increase of RM26.58 million compared with RM1.78 million reported in the corresponding period of the previous financial year (FY2021) from growth of the biopharmaceutical business comprising of immunotherapy and cell therapies as well as COVID-19-related products and services.

Key Points: 
  • For the financial year ended 30 June 2022 (FY2022), Malaysian Genomics registered revenue of RM28.36 million, which is an increase of RM26.58 million compared with RM1.78 million reported in the corresponding period of the previous financial year (FY2021) from growth of the biopharmaceutical business comprising of immunotherapy and cell therapies as well as COVID-19-related products and services.
  • The Group recorded PBT of RM6.18 million for FY2022 compared with LBT of RM4.29 million in FY2021 mainly due to higher revenue as a result of higher margin as well as cost efficiencies.
  • Malaysian Genomics Resource Centre Berhad ("Malaysian Genomics" or "the Group") is a leading genomics and biopharmaceutical company based in Southeast Asia.
  • From pioneering work in genome sequencing, bioinformatics analysis, and genetic screening services, Malaysian Genomics has expanded into the biopharmaceutical sector with the manufacturing of cell therapies including immunotherapy for various types of cancer.

Malaysian Genomics Signs MoU with Ajlan to explore distribution of biopharmaceutical and genetic screening services in MENA region

Retrieved on: 
Monday, August 29, 2022

As part of the MoU, the parties will explore the feasibility of Ajlan becoming a marketing and distribution representative for Malaysian Genomics for genetic screening tests, mesenchymal stem cell and exosome products.

Key Points: 
  • As part of the MoU, the parties will explore the feasibility of Ajlan becoming a marketing and distribution representative for Malaysian Genomics for genetic screening tests, mesenchymal stem cell and exosome products.
  • Malaysian Genomics on its part will analyse samples for genetic screening tests as well as provide Ajlan with genomic and bioinformatics expertise to bid for projects through Ajlan.
  • Malaysian Genomics Resource Centre Berhad ("Malaysian Genomics" or "the Group") is a leading genomics and biopharmaceutical company based in Southeast Asia.
  • From pioneering work in genome sequencing, bioinformatics analysis, and genetic screening services, Malaysian Genomics has expanded into the biopharmaceutical sector with the manufacturing of cell therapies including immunotherapy for various types of cancer.